F

or an early-stage biotech company, raising venture capital funding for the first time is a crucial milestone. And when you look at all the baby’s-first-financing announcements of the past few years, there’s something going on that Atlas Venture VC Bruce Booth calls “so counterintuitive in a lot of ways.”

New data show that the number of life sciences companies that reach that pivotal moment has stayed flat over the past few years. But the amount of money being invested in these first financings is rising, indicating that when companies do manage to get a first big investment, they’re getting more money. The figures come from PitchBook, a company that analyzes and sells data on the private markets.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy